Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street
--------------------------------------------------------------------
Source: Zero Hedge
Published: 2026-04-24 23:15 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Business, Health, Financial Markets
--------------------------------------------------------------------
Snippet:
Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts.
--------------------------------------------------------------------